Another multicenter study of patients with stage 3 or 4 CKD, SHPT, and vitamin D insufficiency showed that the PTH lowering effect of ER calcifediol was independent of the CKD stage and such treatment did not bring any adverse events [139]. The gene discussed is PTH; the disease is chronic kidney disease.